Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001248
Abstract: Abstract: Sodium–glucose cotransporter-2 inhibitors were approved as adjunct therapy for the management of type 2 diabetes and have become a high-level recommendation for this population with cardiorenal metabolic syndrome. In addition, evidence continues to grow… read more here.
Keywords: metabolic syndrome; cardiorenal metabolic; sodium glucose; glucose cotransporter ... See more keywords
Effects of sodium‐glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13696
Abstract: Diabetes mellitus is strongly linked to high risk of cardiovascular and renal disorders. Diabetes management requires coordinated efforts to manage multiple cardiometabolic risk factors. Diabetes mellitus is also associated with poor outcome in patients after… read more here.
Keywords: sodium glucose; effects sodium; cotransporter inhibitors; cardiorenal metabolic ... See more keywords